Investor
ENAVATE SCIENCES GP, LLC
CIK 0001953107 · filed 2026-02-17 · SEC filing
13F book
$506.8M
Positions
7
Largest name
28.1%
Zenas BioPharma, Inc. · ZBIO
Est. mark
—
Need a prior quarter to estimate
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Zenas BioPharma, Inc. | ZBIO | 3.92M | $142.3M | 28.1% | — | Held |
| Immunome Inc. | IMNM | 4.77M | $102.4M | 20.2% | — | Held |
| Sionna Therapeutics, Inc. | SION | 2.48M | $101.9M | 20.1% | — | Held |
| Upstream Bio, Inc. | UPB | 2.46M | $66.8M | 13.2% | — | Held |
| Compass Therapeutics, Inc. | CMPX | 7.79M | $41.8M | 8.3% | — | Held |
| Bridgebio Oncology Therapeut | — | 2.63M | $32.9M | 6.5% | — | Held |
| Camp4 Therapeutics Corp | CAMP | 3.04M | $18.6M | 3.7% | — | Held |
Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.